Henry Schein Reports Record First-Quarter 2021 Financial Results from Continuing Operations
Henry Schein reported record Q1 financial results with total net sales of $2.9 billion, a 20.4% increase year-over-year. This surge was driven by 14.9% internal growth in local currencies, alongside contributions from acquisitions and foreign currency exchange. GAAP net income rose to $166 million ($1.16 per diluted share), up from $130.5 million ($0.91 per diluted share) in Q1 2020. The company also raised its 2021 non-GAAP EPS guidance to at least $3.70. Despite challenges from the pandemic, Henry Schein's performance reflects strong operational execution.
- Total net sales increased by 20.4% to $2.9 billion.
- GAAP net income grew to $166 million, or $1.16 per diluted share.
- Raised 2021 non-GAAP diluted EPS guidance to at least $3.70.
- Global Medical sales excluding PPE and COVID-19 products decreased by 6.8%.
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported record first-quarter financial results from continuing operations. Results from continuing operations exclude contributions from Henry Schein’s former Animal Health business, which was spun off in February 2019 to form a new publicly traded company, Covetrus (Nasdaq: CVET).
Total net sales for the quarter ended March 27, 2021, were
GAAP net income attributable to Henry Schein, Inc. from continuing operations for the first quarter of 2021 was
“We are pleased with exceptional first-quarter global financial performance versus the comparable prior-year period, and also compared to the first quarter of 2019, which is the result of planning and excellent execution across all of our businesses. We also delivered a very strong operating margin for the quarter. While end markets in most geographies still face challenges due to the ongoing pandemic, the overall market recovery and our improving financial results have continued. Our positive momentum reflects the adaptiveness of our business model as well as the commitment of Team Schein Members to our customers and our communities,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Throughout these unprecedented times, Henry Schein has remained focused on the safety of our team and on responding to our customers’ needs, as well as on driving innovation, gaining market share, enhancing our margin profile, and optimizing our cost structure. We believe all of this positions us well to continue to drive earnings growth and create value over the long-term.”
Global Dental sales for the first quarter of 2021 of
Global Dental consumable merchandise internal sales increased by
“For the first quarter, our dental sales in both North America and international markets were strong, including significant growth in North America dental equipment sales versus the fourth quarter of 2020,” noted Mr. Bergman. “Global Dental Specialty sales were also strong with year-over-year internal growth of
Global Medical sales for the first quarter of 2021 of
“We are pleased to report strong double-digit global Medical sales growth during the first quarter. We expect the physician, ambulatory surgery center, alternate care and home health markets to improve over time as infection levels abate and patient volumes normalize. That said, we expect COVID-19 test sales to decline, primarily as a result of unit price erosion,” remarked Mr. Bergman.
“While sales of PPE products have begun to moderate from recent quarterly growth rates in both our Dental and Medical businesses, we expect PPE sales will remain at elevated levels as dentists and physicians implement new standard-of-care best practices,” said Mr. Bergman.
Global Technology and Value-Added Services sales of
“Global Technology and Value-Added Services sales have steadily improved over the last several quarters, with Henry Schein One internal sales in local currencies increasing by
Stock Repurchase Plan
During the first quarter of 2021, the Company repurchased approximately 1.3 million shares of its common stock at an average price of
Financial Guidance
Henry Schein today raised guidance for 2021 non-GAAP diluted EPS from continuing operations. At this time, the Company is not providing guidance for 2021 GAAP diluted EPS from continuing operations as it is unable to provide an accurate estimate of expenses related to the ongoing restructuring initiative. Financial guidance is as follows:
-
2021 non-GAAP diluted EPS from continuing operations attributable to Henry Schein, Inc. is expected to be at or above
$3.70 , representing a floor for fiscal 2021. - Guidance for 2021 non-GAAP diluted EPS attributable to Henry Schein, Inc. is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of future share repurchases, potential future acquisitions, if any, or restructuring expenses. Guidance also assumes foreign exchange rates that are generally consistent with current levels, and that end markets remain stable and are consistent with current market conditions. Guidance does not assume any material adverse market changes associated with COVID-19.
Adjustments to Projected 2021 Non-GAAP Diluted EPS
The Company has provided guidance for 2021 non-GAAP diluted EPS from continuing operations, as noted above. A reconciliation to the Company’s projected 2021 diluted EPS from continuing operations prepared on a GAAP basis is not provided because the Company is unable to provide without unreasonable effort an estimate of costs related to an ongoing restructuring program to mitigate stranded costs and drive additional operating efficiencies, including the corresponding tax effect that will be included in the Company’s 2021 diluted EPS from continuing operations prepared on a GAAP basis. The inability to provide these reconciliations is due to the uncertainty and inherent difficulty of predicting the occurrence, magnitude, financial impact and the timing of related costs. Management does not believe these items are representative of the Company’s underlying business performance. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
First Quarter 2021 Conference Call Webcast
The Company will hold a conference call to discuss first-quarter 2021 financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call through Henry Schein’s website by visiting www.henryschein.com/IRwebcasts. In addition, a replay will be available beginning shortly after the call has ended for a period of one week.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 20,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries and territories. The Company's sales reached
For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.
Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements include EPS guidance and are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019 (COVID-19) on the Company, its results of operations, liquidity, and financial condition (including any estimates of the impact on these items), the rate and consistency with which dental and other practices resume or maintain normal operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”) and COVID-19 related product sales and inventory levels and whether additional resurgences of the virus will adversely impact the resumption of normal operations, the impact of restructuring programs as well as of any future acquisitions, and more generally current expectations regarding performance in current and future periods. Forward looking statements also include the (i) ability of the Company to make additional testing available, the nature of those tests and the number of tests intended to be made available and the timing for availability, the nature of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been, or will not have been, independently verified under normal FDA procedures and (ii) potential for the Company to distribute the COVID-19 vaccines and ancillary supplies.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: risks associated with COVID-19, as well as other disease outbreaks, epidemics, pandemics, or similar wide spread public health concerns and other natural disasters or acts of terrorism; our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; the potential repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic and political conditions, including international trade agreements and potential trade barriers; failure to comply with existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the confidentiality of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation; litigation risks; new or unanticipated litigation developments and the status of litigation matters; cyberattacks or other privacy or data security breaches; risks associated with our global operations; our dependence on our senior management, as well as employee hiring and retention; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.
Included within the press release are non-GAAP financial measures that supplement the Company’s Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company’s actual results prepared under GAAP to exclude certain items. In the schedules attached to this press release, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.
(TABLES TO FOLLOW)
HENRY SCHEIN, INC. |
||||||
CONSOLIDATED STATEMENTS OF INCOME |
||||||
(in thousands, except per share data) |
||||||
(unaudited) |
||||||
|
Three Months Ended |
|||||
|
March 27, |
|
March 28, |
|||
|
2021 |
|
2020 |
|||
|
|
|
|
|
||
Net sales |
$ |
2,924,961 |
$ |
2,428,871 |
||
Cost of sales |
|
2,034,110 |
|
1,682,857 |
||
Gross profit |
|
890,851 |
|
746,014 |
||
Operating expenses: |
|
|
|
|
||
Selling, general and administrative |
|
657,992 |
|
567,362 |
||
Restructuring costs |
|
2,931 |
|
4,787 |
||
Operating income |
|
229,928 |
|
173,865 |
||
Other income (expense): |
|
|
|
|
||
Interest income |
|
1,983 |
|
3,190 |
||
Interest expense |
|
(6,485) |
|
(7,812) |
||
Other, net |
|
309 |
|
(220) |
||
Income from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interests |
|
225,735 |
|
169,023 |
||
Income taxes |
|
(56,685) |
|
(37,910) |
||
Equity in earnings of affiliates |
|
5,878 |
|
2,734 |
||
Net income from continuing operations |
|
174,928 |
|
133,847 |
||
Loss from discontinued operations |
|
- |
|
(282) |
||
Net Income |
|
174,928 |
|
133,565 |
||
Less: Net income attributable to noncontrolling interests |
|
(8,931) |
|
(3,304) |
||
Net income attributable to Henry Schein, Inc. |
$ |
165,997 |
$ |
130,261 |
||
Amounts attributable to Henry Schein, Inc.: |
|
|
|
|
||
Continuing operations |
$ |
165,997 |
$ |
130,543 |
||
Discontinued operations |
|
- |
|
(282) |
||
Net income attributable to Henry Schein, Inc. |
$ |
165,997 |
$ |
130,261 |
||
|
|
|
|
|
||
Earnings per share from continuing operations attributable to Henry Schein, Inc.: |
|
|
|
|
||
|
|
|
|
|
||
Basic |
$ |
1.17 |
$ |
0.91 |
||
Diluted |
$ |
1.16 |
$ |
0.91 |
||
|
|
|
|
|
||
Loss per share from discontinued operations attributable to Henry Schein, Inc.: |
|
|
|
|
||
|
|
|
|
|
||
Basic |
$ |
- |
$ |
0.00 |
||
Diluted |
$ |
- |
$ |
0.00 |
||
|
|
|
|
|
||
Earnings per share attributable to Henry Schein, Inc.: |
|
|
|
|
||
|
|
|
|
|
||
Basic |
$ |
1.17 |
$ |
0.91 |
||
Diluted |
$ |
1.16 |
$ |
0.91 |
||
|
|
|
|
|
||
Weighted-average common shares outstanding: |
|
|
|
|
||
Basic |
|
142,298 |
|
142,967 |
||
Diluted |
|
143,398 |
|
143,095 |
||
HENRY SCHEIN, INC. |
||||||
CONSOLIDATED BALANCE SHEETS |
||||||
(in thousands, except share and per share data) |
||||||
|
March 27, |
|
December 26, |
|||
|
2021 |
|
2020 |
|||
|
(unaudited) |
|
|
|
||
ASSETS |
|
|
|
|
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
$ |
144,538 |
$ |
421,185 |
||
Accounts receivable, net of reserves of |
|
1,317,546 |
|
1,424,787 |
||
Inventories, net |
|
1,626,185 |
|
1,512,499 |
||
Prepaid expenses and other |
|
482,356 |
|
432,944 |
||
Total current assets |
|
3,570,625 |
|
3,791,415 |
||
Property and equipment, net |
|
353,248 |
|
342,004 |
||
Operating lease right-of-use assets |
|
301,759 |
|
288,847 |
||
Goodwill |
|
2,587,438 |
|
2,504,392 |
||
Other intangibles, net |
|
597,619 |
|
479,429 |
||
Investments and other |
|
369,231 |
|
366,445 |
||
Total assets |
$ |
7,779,920 |
$ |
7,772,532 |
||
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
||
Current liabilities: |
|
|
|
|
||
Accounts payable |
$ |
909,575 |
$ |
1,005,655 |
||
Bank credit lines |
|
67,415 |
|
73,366 |
||
Current maturities of long-term debt |
|
111,176 |
|
109,836 |
||
Operating lease liabilities |
|
68,580 |
|
64,716 |
||
Accrued expenses: |
|
|
|
|
||
Payroll and related |
|
286,106 |
|
295,329 |
||
Taxes |
|
146,755 |
|
138,671 |
||
Other |
|
533,161 |
|
595,529 |
||
Total current liabilities |
|
2,122,768 |
|
2,283,102 |
||
Long-term debt |
|
506,461 |
|
515,773 |
||
Deferred income taxes |
|
42,254 |
|
30,065 |
||
Operating lease liabilities |
|
248,624 |
|
238,727 |
||
Other liabilities |
|
410,184 |
|
392,781 |
||
Total liabilities |
|
3,330,291 |
|
3,460,448 |
||
|
|
|
|
|
||
Redeemable noncontrolling interests |
|
452,899 |
|
327,699 |
||
Commitments and contingencies |
|
|
|
|
||
|
|
|
|
|
||
Stockholders' equity: |
|
|
|
|
||
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding |
|
- |
|
- |
||
Common stock, $.01 par value, 480,000,000 shares authorized, 141,310,113 outstanding on March 27, 2021 and 142,462,571 outstanding on December 26, 2020 |
|
1,413 |
|
1,425 |
||
Additional paid-in capital |
|
- |
|
- |
||
Retained earnings |
|
3,493,060 |
|
3,454,831 |
||
Accumulated other comprehensive loss |
|
(136,305) |
|
(108,084) |
||
Total Henry Schein, Inc. stockholders' equity |
|
3,358,168 |
|
3,348,172 |
||
Noncontrolling interests |
|
638,562 |
|
636,213 |
||
Total stockholders' equity |
|
3,996,730 |
|
3,984,385 |
||
Total liabilities, redeemable noncontrolling interests and stockholders' equity |
$ |
7,779,920 |
$ |
7,772,532 |
||
|
|
|
|
|
||
HENRY SCHEIN, INC. |
||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||
(in thousands, unaudited) |
||||||
|
Three Months Ended |
|||||
|
March 27, |
|
March 28, |
|||
|
2021 |
|
2020 |
|||
|
|
|
|
|
||
Cash flows from operating activities: |
|
|
|
|
||
Net income |
$ |
174,928 |
$ |
133,565 |
||
Loss from discontinued operations |
|
- |
|
(282) |
||
Income from continuing operations |
|
174,928 |
|
133,847 |
||
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||
Depreciation and amortization |
|
49,363 |
|
46,983 |
||
Impairment charge on intangible assets |
|
- |
|
2,000 |
||
Stock-based compensation (credit) expense |
|
12,790 |
|
(17,514) |
||
Provision for (benefit from) losses on trade and other accounts receivable |
|
(2,696) |
|
14,543 |
||
Provision for deferred income taxes |
|
11,171 |
|
2,645 |
||
Equity in earnings of affiliates |
|
(5,878) |
|
(2,734) |
||
Distributions from equity affiliates |
|
5,139 |
|
2,413 |
||
Changes in unrecognized tax benefits |
|
2,804 |
|
(1,575) |
||
Other |
|
35 |
|
(13,924) |
||
Changes in operating assets and liabilities, net of acquisitions: |
|
|
|
|
||
Accounts receivable |
|
118,795 |
|
(1,283) |
||
Inventories |
|
(78,085) |
|
73,038 |
||
Other current assets |
|
(45,310) |
|
(22,002) |
||
Accounts payable and accrued expenses |
|
(179,725) |
|
(137,680) |
||
Net cash provided by operating activities from continuing operations |
|
63,331 |
|
78,757 |
||
Net cash used in operating activities from discontinued operations |
|
- |
|
(282) |
||
Net cash provided by operating activities |
|
63,331 |
|
78,475 |
||
|
|
|
|
|
||
Cash flows from investing activities: |
|
|
|
|
||
Purchases of fixed assets |
|
(13,843) |
|
(23,008) |
||
Payments related to equity investments and business acquisitions, net of cash acquired |
|
(204,027) |
|
(37,947) |
||
Proceeds from sale of equity investment |
|
- |
|
12,000 |
||
Repayments from loan to affiliate |
|
139 |
|
1,137 |
||
Other |
|
(5,513) |
|
(5,787) |
||
Net cash used in investing activities from continuing operations |
|
(223,244) |
|
(53,605) |
||
Net cash used in investing activities from discontinued operations |
|
- |
|
- |
||
Net cash used in investing activities |
|
(223,244) |
|
(53,605) |
||
|
|
|
|
|
||
Cash flows from financing activities: |
|
|
|
|
||
Net change in bank borrowings |
|
(241) |
|
358,639 |
||
Proceeds from issuance of long-term debt |
|
- |
|
250,000 |
||
Principal payments for long-term debt |
|
(17,781) |
|
(8,478) |
||
Debt issuance costs |
|
(85) |
|
(58) |
||
Payments for repurchases of common stock |
|
(88,659) |
|
(73,789) |
||
Payments for taxes related to shares withheld for employee taxes |
|
(6,158) |
|
(13,155) |
||
Distributions to noncontrolling shareholders |
|
(6,520) |
|
(3,664) |
||
Acquisitions of noncontrolling interests in subsidiaries |
|
- |
|
(14,925) |
||
Payments to Henry Schein Animal Health Business |
|
- |
|
(2,962) |
||
Net cash provided by (used in) financing activities from continuing operations |
|
(119,444) |
|
491,608 |
||
Net cash provided by financing activities from discontinued operations |
|
- |
|
282 |
||
Net cash provided by (used in) financing activities |
|
(119,444) |
|
491,890 |
||
|
|
|
|
|
||
Effect of exchange rate changes on cash and cash equivalents from continuing operations |
|
2,710 |
|
(5,489) |
||
Effect of exchange rate changes on cash and cash equivalents from discontinued operations |
|
- |
|
- |
||
Net change in cash and cash equivalents from continuing operations |
|
(276,647) |
|
511,271 |
||
Net change in cash and cash equivalents from discontinued operations |
|
- |
|
- |
||
Cash and cash equivalents, beginning of period |
|
421,185 |
|
106,097 |
||
Cash and cash equivalents, end of period |
$ |
144,538 |
$ |
617,368 |
||
Exhibit A - First Quarter Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
||||||||||||||||
Henry Schein, Inc. |
||||||||||||||||
2021 First Quarter |
||||||||||||||||
Sales Summary |
||||||||||||||||
(in thousands) |
||||||||||||||||
(unaudited) |
||||||||||||||||
|
||||||||||||||||
Q1 2021 over Q1 2020 |
||||||||||||||||
|
||||||||||||||||
Global |
Q1 2021 |
|
Q1 2020 |
|
Total Sales
|
|
Foreign
|
|
Local
|
|
Acquisition
|
|
Local
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dental |
$ |
1,788,928 |
|
$ |
1,475,076 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical |
|
993,037 |
|
|
800,688 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Health Care Distribution |
|
2,781,965 |
|
|
2,275,764 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Technology and value-added services |
|
142,996 |
|
|
131,965 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total excluding Corporate TSA Revenue |
|
2,924,961 |
|
|
2,407,729 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate TSA revenues (1) |
|
- |
|
|
21,142 |
|
n/a |
|
n/a |
|
n/a |
|
n/a |
|
n/a |
|
Total Global |
$ |
2,924,961 |
|
$ |
2,428,871 |
|
|
|
|
|
|
|
|
|
|
|
North America |
Q1 2021 |
|
Q1 2020 |
|
Total Sales
|
|
Foreign
|
|
Local
|
|
Acquisition
|
|
Local
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dental |
$ |
1,044,783 |
|
$ |
888,372 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical |
|
965,127 |
|
|
778,028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Health Care Distribution |
|
2,009,910 |
|
|
1,666,400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Technology and value-added services |
|
121,937 |
|
|
113,498 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total excluding Corporate TSA Revenue |
|
2,131,847 |
|
|
1,779,898 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate TSA revenues (1) |
|
- |
|
|
- |
|
n/a |
|
n/a |
|
n/a |
|
n/a |
|
n/a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total North America |
$ |
2,131,847 |
|
$ |
1,779,898 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International |
Q1 2021 |
|
Q1 2020 |
|
Total Sales
|
|
Foreign
|
|
Local
|
|
Acquisition
|
|
Local
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dental |
$ |
744,145 |
|
$ |
586,704 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical |
|
27,910 |
|
|
22,660 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Health Care Distribution |
|
772,055 |
|
|
609,364 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Technology and value-added services |
|
21,059 |
|
|
18,467 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total excluding Corporate TSA Revenue |
|
793,114 |
|
|
627,831 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate TSA revenues (1) |
|
- |
|
|
21,142 |
|
n/a |
|
n/a |
|
n/a |
|
n/a |
|
n/a |
|
Total International |
$ |
793,114 |
|
$ |
648,973 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. |
||||||||||||||||
Exhibit B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Henry Schein, Inc. |
||||||||
2021 First Quarter |
||||||||
Reconciliation of reported GAAP net income from continuing operations and |
||||||||
diluted EPS from continuing operations attributable to Henry Schein, Inc. |
||||||||
to non-GAAP net income from continuing operations and |
||||||||
diluted EPS from continuing operations attributable to Henry Schein, Inc. |
||||||||
(in thousands, except per share data) |
||||||||
(unaudited) |
||||||||
|
|
First Quarter |
|
|||||
|
|
|
|
|
|
|
% |
|
|
|
2021 |
|
|
2020 |
|
Growth |
|
Net Income from continuing operations attributable to Henry Schein, Inc. |
$ |
165,997 |
|
$ |
130,543 |
|
27.2 |
% |
Diluted EPS from continuing operations attributable to Henry Schein, Inc. |
$ |
1.16 |
|
$ |
0.91 |
|
27.5 |
% |
|
|
|
|
|
|
|
|
|
Non-GAAP Adjustments |
|
|
|
|
|
|
|
|
Restructuring costs - Pre-tax (1) |
$ |
2,931 |
|
$ |
4,787 |
|
|
|
Income tax benefit for restructuring costs (1) |
|
(733) |
|
|
(1,197) |
|
|
|
Settlement and litigation costs - Pre-tax (2) |
|
12,750 |
|
|
- |
|
|
|
Income tax benefit for settlement and litigation costs (2) |
|
(3,202) |
|
|
- |
|
|
|
Total non-GAAP adjustments to Net Income from continuing operations |
$ |
11,746 |
|
$ |
3,590 |
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjustments to diluted EPS from continuing operations |
$ |
0.08 |
|
$ |
0.03 |
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Net Income from continuing operations attributable to Henry Schein, Inc. |
$ |
177,743 |
|
$ |
134,133 |
|
32.5 |
% |
Non-GAAP diluted EPS from continuing operations attributable to Henry Schein, Inc. |
$ |
1.24 |
|
$ |
0.94 |
|
31.9 |
% |
Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. Earnings per share numbers may not sum due to rounding.
(1) |
Represents Q1 2021 restructuring costs of |
|
(2) |
Represents a Q1 2021 pre-tax charge of |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005622/en/
FAQ
What were Henry Schein's Q1 financial results for 2021?
What is the guidance for Henry Schein's 2021 non-GAAP diluted EPS?
How did the pandemic affect Henry Schein's sales in Q1 2021?
